Okusa, Mark D. A2A adenosine receptor: a novel therapeutic target in renal disease. Am J Physiol Renal Physiol 282: F10-F18, 2002.-Present strategies in the treatment of inflammatory renal injury have focused on developing agents that specifically target individual mechanisms thought to contribute toward the pathogenesis of the disease. Such an approach is hindered by redundancies in the inflammatory cascade, rendering intervention suboptimal. The A 2A adenosine receptor (A2A-AR) is a member of the family of guanine nucleotide binding proteins and has become a focus of major interest primarily because of its ability to broadly inactivate the inflammatory cascade. This review summarizes our present knowledge regarding the molecular biology and pharmacology of A 2A-ARs as well as the physiological effects of activation of A 2A-ARs in the kidney. We also review our recent experience in targeting this receptor subtype in abrogating the inflammatory cascade in ischemia-reperfusion injury.
inflammation; ATL-146e; ZM-243185; ischemia-reperfusion; acute renal failure ADENOSINE, GENERATED LOCALLY in tissue by conditions that produce hypoxia, ischemia, or inflammation, mediates a variety of physiological functions. The renal effects mediated by adenosine are heterogeneous, due in part to activation of multiple adenosine receptor subtypes that are localized in different regions of the kidney. Traditionally, adenosine has been thought to play a critical role in the local regulation of blood flow, but, more recently, evidence has been accumulating that adenosine also has potent effects in modulating inflammatory processes. This review summarizes present knowledge on the characteristics of one subtype, the A 2A adenosine receptor (A 2A -AR) and its potential role in treating and preventing renal injury.
PHARMACOLOGY AND MOLECULAR BIOLOGY OF A2A ADENOSINE RECEPTORS

Adenosine Receptor Subtypes
Adenosine and adenine nucleotides bind to P 1 and P 2 receptors, respectively (9) . P 2 receptors that bind adenine nucleotides, uracil nucleotides, and/or diadenine polyphosphates are composed of ligand-gated channels (P 2X ) and guanine nucleotide binding protein (G protein)-coupled receptors (P 2Y ) (43) . Adenosine, on the other hand, binds to P 1 purinergic receptors, which are members of the G protein-coupled receptor family. Four subtypes of adenosine receptors have been cloned: A 1 , A 2A , A 2B, and A 3 (for a review, see Refs. 41 and 51) . The four subtypes have the hallmark structural characteristics that are common to G protein-coupled receptors, including seven putative transmembranespanning domains, an extracellular NH 2 terminus, cytoplasmic COOH terminus, and a third intracellular loop that is important in binding G proteins. The first adenosine receptors to be cloned, RDC7 (38) and RDC8 (39), were originally isolated as "orphan" cDNAs. On the basis of their binding properties to pharmacological agents and their effects on adenylyl cyclase, RDC7 and RDC8 were shown to encode canine A 1 -and A 2A -ARs, respectively. Subsequently, adenosine receptor orthologs and homologs were identified in other species, including humans (40, 57, (66) (67) (68) 84) . When the amino acid sequences of all four human adenosine receptor subtypes were compared, they were found to have an overall identity of 30% and a transmembrane domain identity of 45%. They were also found to have pharmacological properties distinct from those of other species. The human A 1 -, A 2A -, A 2B -, and A 3 -ARs are proteins comprising 326, 412, 332, and 318 amino acids, respectively (42) . The receptors can be distinguished pharmacologically by their ability to bind selective ligands and their use of distinct signaling pathways (41, 51) . Table 1 summarizes ligands and their affinities to adenosine receptor subtypes as well as major signaling pathways.
A 2A Adenosine Receptors
The A 2A -AR cDNA, which has been cloned from several species including humans (53) , encodes a protein of ϳ45 kDa, larger than the molecular masses of the other subtypes. This is primarily due to the additional 80-90 amino acids of the COOH-terminal tail. The overall amino acid identity is Ͼ90% among species, with most of the differences occurring in the second extracellular loop and the long COOH-terminal domain. The COOH-terminal domain has several serine and threonine residues that are potential phosphorylation sites. It is well known the A 2A -ARs undergo rapid agonist-induced desensitization associated with phosphorylation of the receptor (55) . A 2A -ARs stimulate adenylyl cyclase and increase the production of cAMP by coupling to stimulatory G proteins (G s ) or to G olf in certain tissues in which G olf is expressed as the primary stimulatory G protein (29) . In addition to the cAMP-protein kinase A (PKA) pathway, recent studies indicate that serine/threonine protein phosphatase (61), mitogen-activated protein kinase (MAP kinase) (71, 72) , PKC (56) , and phospholipase D (83) may participate in mediating the effects of A 2A -AR activation.
LOCALIZATION AND FUNCTIONAL EFFECTS OF A2A ADENOSINE RECEPTORS IN THE KIDNEY
Determining the adenosine receptor subtypes that mediate specific effects of adenosine in the kidney has been difficult for several reasons. First, the low abundance of multiple subtypes in many tissues, including kidney, hinders detection by standard methods. Second, specific pharmacological reagents for the charac- (64) . More recently, a peptide antibody was developed that identified A 1 -ARs in afferent arterioles, mesangial cells, proximal convoluted tubules, medullary collecting ducts, and papillary surface epithelium of the kidney (75) .
The functional effects of adenosine on renal hemodynamics have been reviewed recently (45) . Drury and Szent-Gyorgi (19) reported in 1929 that adenosine produced a marked reduction in renal blood and urine flow. Early studies demonstrated biphasic effects of adenosine with an initial transient vasoconstriction followed by vasodilation, effects mediated by A 1 -and A 2 -ARs, respectively (45) . Defining the functional effects of the A 2A -AR subtype has become possible with the availability of selective A 2A agonists. Infusion of CGS-21680, a selective A 2A agonist, produced an increase in renal blood flow and glomerular filtration rate (37) . With the use of a laser Doppler probe, CGS-21680 was found to increase medullary blood flow to 184% of control without a change in cortical blood flow (37) . Because all blood flow to the renal medulla must pass through the OMDVR, Silldorff et al. (73) isolated OMDVR from rats, perfused them in vitro, and examined the vasoactive properties of CGS-21680. They Table 1 Shown are inhibition constant values (nM) to inhibit radioligand binding to recombinant human adenosine receptors (ARs), with reference nos. in parentheses. Affinity of ATL-146e, a newly developed, highly selective A2A agonist, and CGS-21680, an A2A-AR agonist, for A2A-ARs was corrected for binding to A2A high-affinity sites (50) . ZM-243185, a selective A2A antagonist; MAPK, mitogen-activated protein kinase; CPA, N 6 -cyclopentyladenosine; NECA, 5Ј-N-ethylcarboxiamidoadenosine; R-PIA, R-N 6 -phenylisopropyladenosine.
. Comparative affinities of A 2A ligands for human adenosine receptor subtypes and signaling elements
found that the vasoconstrictive effects of angiotensin II were inhibited in the presence of CGS-21680 but that CGS-21680 had no effect when applied to vessels alone in the absence of angiotensin II. 
A2A ADENOSINE RECEPTORS IN INFLAMMATION
A 2A Adenosine Receptor Expression on Hematopoietic Cells
In addition to the renal vascular and hemodynamic effects of adenosine, studies over the last 10 years have indicated that adenosine has a direct effect on hematopoietic and endothelial cells to reduce inflammation (for a review, see Ref. 42) . Given the fact that A 2A -ARs are expressed in a variety of hematopoietic cell types, i.e., monocytes, lymphocytes, neutrophils, basophils, and mast cells, all of which share a common stem cell source in the bone marrow (23) , this receptor subtype is ideally suited to modulate inflammatory processes. Evidence for an anti-inflammatory role of A 2A -AR activation comes from a variety of studies both in vivo and in vitro.
A large body of evidence suggests that the major signaling pathway that links A 2A -receptor activation and reduction of inflammation is the cAMP-PKA pathway (23, 78) . A 2A agonists increase cAMP in a dosedependent manner, an effect that is enhanced in the presence of a phosphodiesterase (PDE) inhibitor (29) . Furthermore, several studies indicate that inhibitors of PKA block the anti-inflammatory action of A 2A agonists (44, 49, 79) . In tumor necrosis factor (TNF)-␣-activated human neutrophils, ATL-146 ester (e) in the presence of rolipram, a PDE type IV (PDE 4) inhibitor, increased cAMP and decreased human neutrophil oxidative activity. These results suggest that the decrease in neutrophil oxidative activity produced by the selective activation of A 2A -ARs expressed on neutrophils may be due to increased cAMP and activation of PKA.
Effect of A 2A Activation on Reactive Oxygen Species
For the past decade, adenosine has been known as a molecule that mediates an anti-inflammatory effect through the activation of A 2A -ARs (13, 70, 77) . This physiological role of endogenous adenosine became apparent after the demonstration that activated neutrophils or endothelial cells release and respond to adenosine (5, 14, 15, 25) . Neutrophils play a critical role in the inflammatory process. They are the most abundant leukocyte in blood and the first to arrive at a site of injury. Several groups of investigators have demonstrated that adenosine, largely through A 2A -ARs, acts on activated neutrophils (17, 23) to reduce oxygen metabolites such as superoxide anion or hydrogen peroxide (14, 17, 63, 69, 70, 79) . These data provide compelling evidence that selective activation of A 2A -ARs decreases neutrophil oxidative activity. Tissue damage is induced, in part, by the migration of neutrophils into damaged tissue and the release of these reactive oxygen species. Adenosine's effect through A 2A -ARs is thought to limit tissue damage (12) .
Effect of A 2A Activation on Neutrophil Adherence
Adenosine also reduces neutrophil adherence to endothelial cells through an effect attributed to A 2A -ARs (8, 16, 22, 89) . Adhesion of neutrophils to endothelial cells occurs through a complex series of events that may involve several classes of adhesion molecules, including selectins, mucin, and other selectin ligands, integrins, and the immunoglobulin superfamily (24, 33, 58, 59) . In particular, the role of intercellular adhesion molecule (ICAM)-1 has been well studied. ICAM-1 (CD-54) is expressed on endothelial cells and binds to counterreceptors on neutrophils, lymphocyte function antigen (LFA-1; CD11␣/CD18), and Mac-1 (CD11␤/CD18). Abundant data have accumulated that demonstrate convincingly that CD11/CD18␤ 2 integrins and ICAM-1 are important in the pathogenesis of ischemic renal injury (11, 18, 26, 32, 33, 58, 59 ). Pselectin and E-selectin, adhesion molecules expressed on endothelial cells thought to be responsible for leukocyte rolling, have also been found to mediate ischemia-reperfusion injury (74) . In human umbilical vein endothelial cells, adenosine reduces the expression of the adhesion molecules E-selectin and vesicular cell adhesion molecule-1 in a dose-dependent manner (7) .
There is accumulating evidence that adenosine regulates adhesion molecule expression. Using monoclonal antibodies and flow cytometry, N-formylmethionylleucylphenlyalanine-induced expression of neutrophil Mac-1 was inhibited by a selective A 2A agonist (88) . More recently, in vivo studies using a selective A 2A agonist, ATL-146e, reduced the heightened expression of renal endothelial cell expression of ICAM-1 and P-selectin induced by ischemia-reperfusion injury (48) . On the other hand, adenosine paradoxically mediates neutrophil chemotaxis via A 1 -ARs (13, 63) . Such a dual effect might protect endothelial cells from the deleterious effects of activated neutrophils yet allow chemotaxis to the site of infection (13) . These data from the use of selective agonists of A 1 and A 2A -ARs suggest a complex interaction between adenosine receptor subtypes and neutrophil adhesion. Adenosine, acting on A 2A -ARs, may reduce inflammation by inhibiting adhesion molecule expression and subsequent neutrophil adherence to endothelial cells. The precise signaling pathways whereby adenosine reduces neutrophil adherence are not known.
A 2A Activation and Cytokines
Monocytes accumulate more slowly at sites of inflammation than neutrophils and contribute to the inflammatory process by producing and releasing cytokines. The results of several studies indicate that the proinflammatory cytokine TNF-␣, is regulated by A 2A -ARs. Mononuclear cells (15-20% monocytes and 80-85% lymphocytes) were cultured in vitro and stimulated with endotoxin (78) . Endotoxin-induced stimulation of TNF-␣ production was inhibited with 5Ј-N-ethylcarboxamidoadenosine and CGS-21680 in a dose-dependent manner. This effect by the selective A 2A agonists was inhibited completely with the addition of ZM-243185, a selective A 2A antagonist. Other studies have also demonstrated that adenosine or adenosine analogs reduce TNF-␣ production by A 2A -AR activation (6, 20, 28, 60) . In human monocytes, lipopolysaccharide-induced production of the proinflammatory cytokines interleukin (IL)-6 and IL-8 was also inhibited by A 2 receptor activation (6). In activated monocytes/macrophages, binding of selective A 2A -AR agonists leads to an inhibition of the proinflammatory cytokine IL-12 (27, 44) . The rank-order potency for the inhibition of IL-12 was CGS-21680 Ͼ IB-N 6 -(3-iodobenzyl)-adenosine-5Ј-N-methyluronamice Ͼ 2-chloro-N 6 -cyclopentyl adenosine (27) . The observation that the inhibitory effect of A 2A -AR agonists on IL-12 is blocked by PKA inhibitors suggests the involvement of the cAMP-PKA pathway (44) . Regulation of IL-12 is not thought to be due to activation of p38 and p42/p44 MAP kinase or phosphorylation of c-Jun terminal kinase (27) . These studies demonstrate the ability of the activation of a single receptor subtype to broadly regulate a number of proinflammatory cytokines.
A 2A Adenosine Receptors Activation Reduces Tissue Injury
On the basis of the evidence that activation of A 2A -ARs regulates factors that attenuate inflammation, studies have been performed using selective A 2A agonists in nonrenal tissue to determine whether activation of A 2A -ARs confers tissue protection. In many of these studies, the observation that A 2A agonist-induced tissue protection was associated with a reduction of factors associated with inflammation suggested that A 2A agonists contribute to tissue protection by attenuating inflammation. Although a direct causal relationship between tissue protection and attenuation of inflammation by A 2A agonists has not been proven, the abundant data suggest this direct link. In dog heart, CGS-21680, a highly selective A 2A agonist, reduced myocardial tissue injury, an effect associated with a decrease in neutrophil accumulation, superoxide generation, and neutrophil adherence to endothelium (31) . Recently, using a lung transplantation model, ATL146e, an agonist that is 50 times more potent than CGS-21680 (62), reduced neutrophil sequestration and microvascular permeability in parallel with a reduction in tissue injury (65) . The role of A 2A -ARs in neuroprotection appears to be more complex due to the role of A 2A -ARs in neural function. Both by immunohistochemistry using a selective A 2A -AR monoclonal antibody and by in situ hybridization, A 2A -ARs have been localized to the striatum, nucleus accumbens, and globus pallidus (53, 86) . A 2A agonists lead to the release of neurotoxic chemical mediators such as glutamate which may augment cerebral ischemia-reperfusion. In contrast, A 2A antagonists, when given before ischemiareperfusion, can lead to a decrease in the release neurotoxic chemicals, leading to a reduction of cerebral damage (86) . This finding is in sharp contrast to what is known about the effects of A 2A agonists on neutrophil function and reperfusion injury in other tissues (31, 48) . Because leukocyte accumulation occurs after the ischemic period and during reperfusion, cerebral tissue protection achieved by A 2A agonists (52) is typically optimal when given during the reperfusion period and not before the ischemic period (86) .
A2A ADENOSINE RECEPTORS IN RENAL DISEASE
Given the possibility of multiple functional consequences by nonspecific activation of adenosine receptors, agents that are targeted to specific A 2A -AR subtypes are potentially important novel therapeutic agents. The foregoing discussion demonstrating the protective effect of A 2A activation in other tissues strongly suggests that selective A 2A agonists could provide a means of reducing tissue injury in kidney. One such compound is ATL-146e, which has been developed and extensively characterized (62, 79) by chemically modifying the structure of adenosine. The high selectivity of ATL-146e for A 2A -ARs is due to substitutions at the C2 and 5Ј positions. Radioligand binding studies indicate that ATL-146e has a higher affinity for A 2A -ARs than the acid form (ATL-146 acid) and a higher affinity and selectivity for A 2A -ARs than the commercially available CGS-21680, a highly selective A 2A agonist ( 
Acute Ischemic Renal Failure
We tested the potential role of A 2A -AR activation in reducing renal injury in a model of acute ischemic renal failure (48) (49) (50) . This model was chosen because of the well-characterized effects of reperfusion on the inflammatory cascade associated with renal ischemiareperfusion injury (36, 76, 82) . Although the pathogenic role of neutrophils in ischemia-reperfusion injury of the kidney has been controversial, many studies have clearly shown that neutrophils and other inflammatory cells accumulate in kidneys subjected to ischemia-reperfusion (10, 54, 80) . We studied both rats and mice and found that ATL-146e, when administered before ischemia and during the period of reperfusion, produced a 70% reduction in the elevation of plasma creatinine produced by ischemia-reperfusion (49) . Significant protection was also observed when ATL-146e administration was delayed and begun immediately at the onset of reperfusion (50) . ATL-146e-induced pres-ervation of renal function was associated with pronounced histological preservation as well (50) . Figure 1 shows the dose-dependent reduction in plasma creatinine by ATL-146e in mice subjected to 32 min of ischemia followed by 24 h of reperfusion (49) . Maximal protection was observed with doses of ATL-146e between 1 and 10 ng ⅐ kg Ϫ1 ⅐ min
Ϫ1
, an effect that was blocked by coadministration of a selective A 2A antagonist (50) or absent in A 2A -knockout mice (Okusa MD, unpublished observations). These results indicate that the effect of ATL-146e in reducing renal injury is A 2A receptor mediated.
Additional studies have been performed to elucidate the mechanism of protection by ATL-146e. These studies demonstrate that A 2A activation reduces neutrophil accumulation, a result that may be due to a decrease in P-selectin and ICAM-1 expression (48) . Furthermore, studies in neutrophils indicate that ATL-146e decreased neutrophil oxidative activity and neutrophil adherence factors (48) . Figure 2 summarizes potential targets for A 2A agonists in reducing renal injury. Evidence from in vitro and in vivo studies suggest that A 2A receptor activation regulates tissue-specific function. Activation of A 2A -ARs on leukocytes could attenuate inflammation by reducing the release of leukocyte free radicals and hydrogen peroxide (14, 17, 63, 69, 70, 79) , the releasing of various leukocyte proteases, and reducing the expression of adhesion molecules such as Mac-1 (88) . Characterization of A 2A -AR expression by microvascular endothelial cells is lacking; however, certain microvascular endothelial cell adhesion molecules may be directly or indirectly regulated by A 2A agonists (48) . There is evidence that reduction of cytokine release by activation of A 2A -ARs on other inflammatory cells such as monocyte/macrophages may potentially reduce renal injury (27, 44) . Although there are several targets for A 2A agonists in mediating tissue protection, not all necessarily participate in the protection observed in ischemia-reperfusion injury of the kidney. Differentiating effects on inflammatory cells and endothelial/smooth muscle cells could lead to a further understanding of the mechanism of action of A 2A agonists as well as of the pathogenesis of ischemiareperfusion injury. The generation of chimeric mice in which the bone marrow of wild-type mice is ablated and repopulated with stem cells from A 2A -knockout mice could address this issue.
The cellular mechanism by which A 2A -ARs produce these effects is likely through an increase in intracellular cAMP and PKA activation, as the effects of A 2A activation on neutrophil oxidative activity were blocked by a PKA inhibitor (48) . An intriguing observation with potential therapeutic implications is the observation that the effects of A 2A activation on neutrophil oxidative activity and adherence were potentiated in the presence of a PDE 4 inhibitor. Both A 2A agonists and PDE inhibitors act along different pathways to increase intracellular cAMP accumulation. We evaluated the effects of combination therapy and found (23) . Smooth muscle cells of the descending vasa recta vasodilate in response to A2A agonists (73) . Last, an effect mediated by A2A agonists in endothelial cells may regulate adhesion molecules (48) and cytokines (7) . ROS, reactive oxygen species; MØ, macrophages; TNF-␣, tumor necrosis factor-␣; NO, nitric oxide.
that treatment with both compounds in combination has a greater effect in reducing renal injury and neutrophil accumulation than the use of either compound alone (49) . Combination therapy using low doses of each agent might be a useful strategy for providing maximal tissue protection by blocking the inflammatory cascade while minimizing the risk of side effects (Fig. 3) . These studies indicate a novel approach to reducing renal injury that takes advantage of the ability of a single receptor to broadly abrogate the inflammatory cascade.
A 2A Adenosine Receptors in Other Renal Diseases
Recent evidence also suggests the potential utility of A 2A agonists in renal transplantation. All renal allografts encounter substantial injury due to the transplant process, which may enhance the antigenicity of the transplanted organ and initiate rejection (18) . Reducing reperfusion injury by A 2A -AR activation may enhance allograft survival. Independent of the effects of A 2A -agonists on reperfusion injury, we have recently shown that activation of A 2A -ARs reduces human leukocyte antigen class I and II expression on human lymphocytes (47) . Direct effects on human leukocyte antigen expression by A 2A agonists may reduce the antigenicity of allografts and provide an additional mechanism for enhanced graft survival.
Additional potential therapeutic applications of A 2A agonists include reducing renal injury associated with nephrotoxins. Contrast-induced acute renal failure is thought to be due in part to renal vasoconstriction (1) and to oxidant injury (3). The latter mechanism forms the basis for the use of N-acetylcysteine in the prevention of acute renal failure from contrast agents (81), whereas adenosine agonists could be protective by intervention of either mechanism. Experimental studies point to adenosine as a candidate in mediating renal vasoconstriction (1), a hypothesis supported by the finding that theophylline, a nonselective adenosine receptor antagonist, prevents the reduction of glomerular filtration rate associated with contrast agents (1, 21) . A 2A -ARs are expressed in afferent and efferent arterioles and induce vasodilation when activated (46) ; thus selective A 2A -agonists could potentially prevent a contrast-induced decrease in glomerular filtration rate. Furthermore, because of the known effects of adenosine in reducing oxidative injury, A 2A agonists could mediate renal protection by reducing the oxidant damage produced by contrast agents.
Cisplatin is an anticancer therapeutic agent that is associated with significant nephrotoxicity due to hemodynamic changes and oxidant injury (4). Antagonizing A 1 -ARs with a selective antagonist, 8-cyclopentyl-1,3-dipropylxanthine, has been shown to decrease renal injury associated with cisplatin (34) . Thus the potential exists for using selective A 2A agonists to counteract oxidant injury and renal vasoconstriction in reducing cisplatin-induced nephrotoxicity.
The known anti-inflammatory effects of A 2A agonists on both neutrophils and mononuclear cells may permit wide-ranging effects on other types of acute inflammatory renal injury. Among these, the involvement of the inflammatory cascade in glomerulonephritis may be a likely target for similar anti-inflammatory strategies with A 2A -AR agonists. Previous studies have demonstrated the potential role of PDE inhibition in suppressing the injury associated with mesangial proliferative glomerulonephritis (85) . This finding along with the foregoing discussion establish the potential for the use of A 2A agonists in glomerulonephritis. The expression of A 2A -ARs on key structures involved in the regulation of glomerular filtration such as afferent and efferent arterioles and mesangial cells could provide the foundation for studies examining chronic models of glomerular disease.
CONCLUSION
Although various strategies have been employed to abrogate the inflammatory cascade of renal injury, activation of A 2A -ARs has emerged as a novel therapeutic approach. Newer agents have been synthesized that are potent and selective for this receptor subtype. Their further development awaits their use in human clinical trials. Fig. 3 . Cellular model demonstrating enhanced effect of combined phosphodiesterase type IV (PDE 4) inhibition and A2A-AR activation. After A2A-AR activation, adenylyl cyclase is activated through Gs proteins, leading to an increase in cAMP-protein kinase A. This pathway is thought to lead to the anti-inflammatory effects of A2A-AR activation. Because PDE4 is activated in inflammation, elevation of cAMP is minimized. In the presence of an inhibitor of PDE4, degradation of cAMP is reduced and the effect of A2A -AR activation is enhanced. PKC, protein kinase C. Courtesy of G. Sullivan (Univ. of Virginia) with modifications.
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